On November 4, HBM HOLDINGS-B posted an Intraday Rise of 5.16% in Regular Trading, with the stock trading at HK$9.97 and turnover of HK$41.80 million.
The latest disclosed catalyst was the company’s November 3 on-market buyback of 500,000 shares for about HK$4.72 million at HK$9.31 to HK$9.69 per share. After the transaction, cumulative repurchases under the current mandate reached 3.8 million shares, or about 0.44% of the shares in issue on the authorization date. The company also issued 41,000 new shares under its share award scheme.
Sector sentiment also improved on November 4, with CXO and innovative drug names broadly stronger. Earlier, the company announced that its core product batoclimab subcutaneous injection had received approval in China for generalized myasthenia gravis, providing additional fundamental context for investor attention.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments